Wilex Reports Completion of Phase I Dose Escalation Trial of Cancer Drug
Posted on: Monday, 28 January 2008, 12:00 CST
Biopharmaceutical firm Wilex has successfully completed a Phase I dose escalation study with its drug candidate WX-UK1 in combination with the chemotherapeutic agent capecitabine in patients with advanced solid tumours.
Twenty-five patients were treated with the combination of both substances. Patients have received once weekly infusions of WX-UK1 for three weeks at various fixed doses and daily capecitabine concomitantly for two weeks. This three-week cycle was repeated until progression or toxicity. The maximum number of treatment cycles was 15 (eleven months). Twenty-three patients completed at least one treatment course with an average of 4.5 treatment courses.
The combination therapy was safe and well tolerated. The typical capecitabine-related adverse events were observed and no apparent changes in the frequencies or intensities of these side effects were reported. No serious adverse events related to WX-UK1 were reported.
Source: Datamonitor
Related Articles
- Research Finds Higher Drug Co-Pays Discourage Patients From Starting Treatment
- Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne
- Only 44.4 Percent of Parkinson's Disease Patients Receive Drug Treatment Within One Year of Being Diagnosed
- Amylin Combination Treatment Found Effective in Obesity Study
- Pramlintide and Leptin Combination Treatment Demonstrates 12.7 Percent Weight Loss in 24-Week Clinical Obesity Study
- Over Half of German Population Favor Combined Treatment of Chinese,Western Medicine
- Stanford Study Evaluates Combined Treatment of Insomnia and Depression
- Relationship Between Release of Platelet/Endothelial Biomarkers and Plasma Levels of Sertraline and N-Desmethylsertraline in Acute Coronary Syndrome Patients Receiving SSRI Treatment for Depression
- The Levels of Soluble Adhesion Molecules in Diabetic and Nondiabetic Patients With Combined Hyperlipoproteinemia and the Effect of Ciprofibrate Therapy
- Combined Treatment of Glioblastoma Patients With Locoregional Pre- Targeted ^Sup 90^Y-Biotin Radioimmunotherapy and Temozolomide
 |
 |
User Comments (0)
RSS Feeds